oxaliplatin in treating patients with relapsed or refractory non-hodgkin's lymphoma

Conditions: Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Waldenström Macroglobulinemia

Summary: phase ii trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-hodgkin's lymphoma. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

objectives: i. determine the response rate to oxaliplatin in patients with relapsed or refractory non-hodgkin's lymphoma. ii. determine the treatment-related toxicity of this drug in these patients. outline: this is a multicenter study. patients are stratified according to histologic subtype (indolent vs aggressive). patients receive oxaliplatin iv over 2 hours on day 1. treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. projected accrual: a maximum of 72 patients will be accrued for this study within 2-3 years.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed recurrent or refractory non-hodgkin's lymphoma (nhl) of any histologic subtype * indolent * follicular small cleaved cell * follicular mixed cell * small lymphocytic * mucosa-associated lymphoid tissue (malt) * monocytoid b-cell * waldenstrom's macroglobulinemia * aggressive * follicular large cell * diffuse large cell * immunoblastic * mantle cell * ki-1+ nhl * peripheral t-cell * angiocentric and angioimmunoblastic * transformed lymphoma * bidimensionally measurable disease * no more than 3 prior treatment regimens as follows: * primary radiotherapy is 1 regimen * combined therapy with radiotherapy and chemotherapy is 1 regimen * alternating therapy is 1 regimen * no known brain metastases * performance status - ecog 0-2 * performance status - karnofsky 50-100% * wbc count at least 3,000/mm\^3 * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 * bilirubin normal * sgot/sgpt no greater than 2.5 times upper limit of normal * creatinine normal * creatinine clearance at least 60 ml/min * no symptomatic congestive heart failure * no unstable angina pectoris * no cardiac arrhythmia * no neuropathy greater than grade 1 * no history of allergy to platinum compounds or antiemetics * no uncontrolled illness * no active infection * not pregnant or nursing * fertile patients must use effective contraception * no concurrent colony-stimulating factors during first course of therapy * at least 4 weeks since prior chemotherapy * at least 4 weeks since prior radiotherapy * no other concurrent investigational drugs * no concurrent antiretroviral therapy for hiv-positive patients